Display options
Cite
Navid F, Mischen BT, Helman LJ. Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines. Sarcoma. 2004;8(1):25-30doi: 10.1080/13577140410001679220.
Navid, F., Mischen, B. T., & Helman, L. J. (2004). Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines. Sarcoma, 8(1), 25-30. https://doi.org/10.1080/13577140410001679220
Navid, Fariba, et al. "Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines." Sarcoma vol. 8,1 (2004): 25-30. doi: https://doi.org/10.1080/13577140410001679220
Navid F, Mischen BT, Helman LJ. Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines. Sarcoma. 2004;8(1):25-30. doi: 10.1080/13577140410001679220. PMID: 18521390; PMCID: PMC2395599.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2004;8(1):25-30. doi: 10.1080/13577140410001679220.

Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines.

Sarcoma

Fariba Navid, Blaine T Mischen, Lee J Helman

Affiliations

  1. Pediatric Oncology Branch National Cancer Institute National Institutes of Health Bethesda MD 20892-1928 USA.

PMID: 18521390 PMCID: PMC2395599 DOI: 10.1080/13577140410001679220

Abstract

Purpose. Transduction of rhabdomyosarcoma (RMS) cells with adenoviral vectors for in vivo and in vitro applications has been limited by the low to absent levels of coxackie and adenovirus receptor (CAR). This study investigates the potential use of low doses of a histone deacetylase inhibitor, depsipeptide (FR901228), currently in Phase II human trials, to enhance adenoviral uptake in six rhabdomyosarcoma cell lines.Methods. Differences in adenoviral uptake in the presence and absence of depsipeptide (FR901228) were assessed using an adenoviral construct tagged with green fluorescent protein. Changes in CAR and alpha(v) integrin expression RMS in response to pretreatment with depsipeptide (FR901128) was determined using RT-PCR.Results. Pretreatment of five of six RMS cell lines with 0.5 ng/ml of depsipeptide (FR901228) for 72 h resulted in increased viral uptake as assessed by green fluorescent protein expression. RT-PCR analysis for CAR showed that in four of these five cell lines, CAR expression was increased 2.8-8.1-fold in cells treated with depsipeptide (FR901228) as compared to control. alpha(v) integrin expression was substantially increased in the one cell line, RH5, which showed increased GFP expression in response to depsipeptide (FR901228) pretreatment but a minimal increase in CAR expression.Conclusions. Depsipeptide (FR901228) can be used as a vehicle to enhance adenoviral transduction in a majority of RMS cells. The mechanism of increased viral uptake appears to mediate via upregulation of CAR.

References

  1. Virology. 2000 Mar 15;268(2):382-90 - PubMed
  2. Cell. 1993 Apr 23;73(2):309-19 - PubMed
  3. J Biol Chem. 1997 Mar 7;272(10):6479-89 - PubMed
  4. Exp Cell Res. 1998 May 25;241(1):126-33 - PubMed
  5. Science. 1997 Feb 28;275(5304):1320-3 - PubMed
  6. J Antibiot (Tokyo). 1994 Mar;47(3):301-10 - PubMed
  7. Blood. 2002 Mar 15;99(6):2248-51 - PubMed
  8. Virology. 1997 May 12;231(2):201-9 - PubMed
  9. Hum Gene Ther. 1998 Jul 1;9(10):1469-79 - PubMed
  10. Hum Gene Ther. 1999 Sep 20;10(14):2407-17 - PubMed
  11. Cancer Res. 2001 Apr 1;61(7):2953-60 - PubMed
  12. Cancer Res. 1992 Apr 15;52(8):2243-7 - PubMed
  13. J Virol. 2000 Jan;74(1):42-8 - PubMed
  14. Invasion Metastasis. 1996;16(2):83-96 - PubMed
  15. Cancer Res. 2001 Sep 1;61(17):6328-30 - PubMed
  16. Gene Ther. 2000 Oct;7(19):1624-30 - PubMed
  17. Cancer Res. 1999 Jan 15;59(2):325-30 - PubMed
  18. J Antibiot (Tokyo). 1994 Mar;47(3):315-23 - PubMed
  19. Cancer Gene Ther. 1994 Mar;1(1):15-20 - PubMed
  20. J Natl Cancer Inst. 1982 Mar;68(3):437-43 - PubMed
  21. J Biol Chem. 2000 May 12;275(19):14729-35 - PubMed
  22. FASEB J. 2002 Jan;16(1):108-10 - PubMed
  23. Gene Ther. 1999 Sep;6(9):1600-10 - PubMed
  24. Biosci Biotechnol Biochem. 1994 Sep;58(9):1579-83 - PubMed
  25. J Immunol Methods. 1986 May 22;89(2):271-7 - PubMed
  26. J Clin Invest. 1989 Sep;84(3):829-39 - PubMed

Publication Types